PETS Quote, Financials, Valuation and Earnings

LifeMD has a net margin of 3.91% compared to PetMed Express's net margin of -9.61%. PetMed Express's return on equity of -0.96% beat LifeMD's return on equity of --.

PetMed Express has a consensus price target of --, signalling downside risk potential of -19.18%. On the other hand LifeMD has an analysts' consensus of $12.00 which suggests that it could grow by 129.45%. Given that LifeMD has higher upside potential than PetMed Express, analysts believe LifeMD is more attractive than PetMed Express.

PetMed Express has a beta of 0.689, which suggesting that the stock is 31.122% less volatile than S&P 500. In comparison LifeMD has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.061%.

PetMed Express has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express pays -166.63% of its earnings as a dividend. LifeMD pays out -15.08% of its earnings as a dividend.

PetMed Express quarterly revenues are $59.6M, which are larger than LifeMD quarterly revenues of $53.4M. PetMed Express's net income of $2.3M is higher than LifeMD's net income of -$5.1M. Notably, PetMed Express's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express is 0.37x versus 1.08x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.

Oruka Therapeutics has a net margin of 3.91% compared to PetMed Express's net margin of --. PetMed Express's return on equity of -0.96% beat Oruka Therapeutics's return on equity of --.

PetMed Express has a consensus price target of --, signalling downside risk potential of -19.18%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 116.16%. Given that Oruka Therapeutics has higher upside potential than PetMed Express, analysts believe Oruka Therapeutics is more attractive than PetMed Express.

PetMed Express has a beta of 0.689, which suggesting that the stock is 31.122% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PetMed Express has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express pays -166.63% of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.

PetMed Express quarterly revenues are $59.6M, which are larger than Oruka Therapeutics quarterly revenues of --. PetMed Express's net income of $2.3M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, PetMed Express's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express is 0.37x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Streamline Health Solutions has a net margin of 3.91% compared to PetMed Express's net margin of -56.03%. PetMed Express's return on equity of -0.96% beat Streamline Health Solutions's return on equity of -54.79%.

PetMed Express has a consensus price target of --, signalling downside risk potential of -19.18%. On the other hand Streamline Health Solutions has an analysts' consensus of $22.50 which suggests that it could fall by -59.02%. Given that Streamline Health Solutions has more downside risk than PetMed Express, analysts believe PetMed Express is more attractive than Streamline Health Solutions.

PetMed Express has a beta of 0.689, which suggesting that the stock is 31.122% less volatile than S&P 500. In comparison Streamline Health Solutions has a beta of 1.552, suggesting its more volatile than the S&P 500 by 55.205%.

PetMed Express has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. Streamline Health Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express pays -166.63% of its earnings as a dividend. Streamline Health Solutions pays out -- of its earnings as a dividend.

PetMed Express quarterly revenues are $59.6M, which are larger than Streamline Health Solutions quarterly revenues of $4.4M. PetMed Express's net income of $2.3M is higher than Streamline Health Solutions's net income of -$2.5M. Notably, PetMed Express's price-to-earnings ratio is -- while Streamline Health Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express is 0.37x versus 0.78x for Streamline Health Solutions. Usually stocks with elevated PS ratios are considered overvalued.

TruBridge has a net margin of 3.91% compared to PetMed Express's net margin of -11.7%. PetMed Express's return on equity of -0.96% beat TruBridge's return on equity of -31.4%.

PetMed Express has a consensus price target of --, signalling downside risk potential of -19.18%. On the other hand TruBridge has an analysts' consensus of $15.60 which suggests that it could fall by -19.6%. Given that TruBridge has more downside risk than PetMed Express, analysts believe PetMed Express is more attractive than TruBridge.

PetMed Express has a beta of 0.689, which suggesting that the stock is 31.122% less volatile than S&P 500. In comparison TruBridge has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.412%.

PetMed Express has a quarterly dividend of $0.30 per share corresponding to a yield of 0%. TruBridge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PetMed Express pays -166.63% of its earnings as a dividend. TruBridge pays out -- of its earnings as a dividend.

PetMed Express quarterly revenues are $59.6M, which are smaller than TruBridge quarterly revenues of $83.8M. PetMed Express's net income of $2.3M is higher than TruBridge's net income of -$9.8M. Notably, PetMed Express's price-to-earnings ratio is -- while TruBridge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PetMed Express is 0.37x versus 0.84x for TruBridge. Usually stocks with elevated PS ratios are considered overvalued.